PMID: 6402913Mar 1, 1983Paper

Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action

The American Journal of Cardiology
C Y ChewR B Petersen

Abstract

The effect of intravenous verapamil on systemic and coronary hemodynamic function was studied at cardiac catheterization in 12 patients with coronary artery disease. Verapamil was administered as a 2-minute bolus (0.145 mg/kg) followed by an infusion (0.005 mg/kg/min). Cardiac output and coronary sinus blood flow were measured by thermodilution techniques. Caliber of the large coronary arteries and of diseased segments was determined from the coronary angiogram using a computer-assisted method. Verapamil reduced mean arterial pressure 14% (p less than 0.001), systemic vascular resistance 21% (p less than 0.01), and stroke work index 16% (p less than 0.001). Coronary vascular resistance decreased 24% (p less than 0.01) with a small increase in coronary sinus blood flow (+13%, difference not significant [NS]). Myocardial oxygen consumption determined in 5 patients showed no significant change with verapamil. Luminal area in 39 coronary lesions was measured in the "normal" portion of the diseased segment and at its maximal constriction, and an estimate of flow resistance in the stenosis was computed. Overall, 50% of "normal" and of diseased coronary segments dilated significantly with verapamil. Stenosis dilation resulted in an av...Continue Reading

References

Nov 1, 1977·American Heart Journal·B N Singh, A H Roche
Feb 1, 1979·Circulation·J FerlinzW S Aronow
Oct 22, 1979·The American Journal of Cardiology·S GoldbergJ A Kastor
Jan 1, 1980·The Journal of Clinical Investigation·S F VatnerA D Pasipoularides
Jun 5, 1980·The New England Journal of Medicine·E AntmanE Braunwald
Apr 9, 1981·The New England Journal of Medicine·S M JohnsonL D Hillis
Jan 1, 1981·The American Journal of Cardiology·P G HugenholtzR W Brower
Dec 1, 1980·The American Journal of Cardiology·J Ferlinz, M E Turbow
Mar 1, 1965·Canadian Journal of Physiology and Pharmacology·K I MELVILLE, B G BENFEY

❮ Previous
Next ❯

Citations

Mar 1, 1985·The American Journal of Cardiology·C R LambertC J Pepine
Mar 15, 1985·The American Journal of Cardiology·J S AlpertI S Ockene
Jun 1, 1986·Australian and New Zealand Journal of Medicine·B G Brown
Feb 1, 1985·Journal of the American College of Cardiology·R L FeldmanC J Pepine
Sep 2, 2009·Journal of Cardiovascular Pharmacology and Therapeutics·Robert A Kloner
Mar 9, 1999·Journal of Cardiovascular Pharmacology·N FerraraF Rengo
May 16, 2020·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jin WangLingzhong Meng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.